IP36-23: Association Between Hyperphosphatemia and Survival in FGFR-Altered Urothelial Cancer Treated With Erdafitinib: A Post Hoc Analysis of the THOR Phase III Randomized Clinical Trial

IP36-23: Association Between Hyperphosphatemia and Survival in FGFR-Altered Urothelial Cancer Treated With Erdafitinib: A Post Hoc Analysis of the THOR Phase III Randomized Clinical Trial

Saturday, May 16, 2026 9:30 AM to 11:30 AM · 1 hr. 59 min. (America/New_York)
147B
Abstract

Log in

See all the content and easy-to-use features by logging in or registering!